Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy-Reference-Cited by-同舟云学术

Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy

Published:2017-05 Issue:4 Volume:39 Page:e183-e186
ISSN:1077-4114
Container-title:Journal of Pediatric Hematology/Oncology
language:en
Short-container-title:

Author:

Ghisoli Maurizio,Rutledge McCarley,Stephens Philip J.,Mennel Robert,Barve Minal,Manley Meghan,Oliai Bahram R.,Murphy Kathleen M.,Manning Luisa,Gutierrez Belen,Rangadass Priyanka,Walker Ashli,Wang Zhaohui,Rao Donald,Adams Ned,Wallraven Gladice,Senzer Neil,Nemunaitis John

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference20 articles.

1. Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997;Bacci;Ann Oncol,2003

2. Survival after recurrence of Ewing’s sarcoma family of tumors;Barker;J Clin Oncol,2005

3. Three-year follow up of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing’s sarcoma;Ghisoli;Mol Ther,2016

4. Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma;McCaughan;J Hematol Oncol,2016

5. Long term follow up: phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANG™) in advanced cancer;Senzer;J Vaccines Vaccin,2013

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Prospects of Furin Inhibitors for Therapeutic Applications;International Journal of Molecular Sciences;2024-08-24

2. Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy;Future Oncology;2024-08-05

3. The proprotein convertase furin in cancer: more than an oncogene;Oncogene;2022-01-07

4. Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer;Clinical Medicine Insights: Oncology;2022-01

5. Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6;Vaccines;2021-10-18